Reduced-dose ipilimumab with standard-dose pembrolizumab: Is less more? Journal Article
| Author: | Postow, M. |
| Article Title: | Reduced-dose ipilimumab with standard-dose pembrolizumab: Is less more? |
| Keywords: | overall survival; drug tolerability; cancer combination chemotherapy; dose response; drug dose reduction; drug efficacy; drug safety; monotherapy; side effect; note; ipilimumab; melanoma; progression free survival; prevalence; adverse outcome; nivolumab; human; priority journal; pembrolizumab |
| Journal Title: | Lancet Oncology |
| Volume: | 18 |
| Issue: | 9 |
| ISSN: | 1470-2045 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2017-09-01 |
| Start Page: | 1144 |
| End Page: | 1145 |
| Language: | English |
| DOI: | 10.1016/s1470-2045(17)30518-1 |
| PROVIDER: | scopus |
| PUBMED: | 28729152 |
| DOI/URL: | |
| Notes: | Note -- Export Date: 1 December 2017 -- Source: Scopus |
